 Glucagon-Like Peptide-2 Receptor
"Glucagon-Like Peptide-2 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor for GLUCAGON-LIKE PEPTIDE 2 (GLP-2) that is expressed on the surface of intestinal cells as well as neural cells. GLP-2 and other peptides act through GLP-2R to regulate cellular responses to BLOOD GLUCOSE, INFLAMMATION, and FOOD INTAKE.
| Descriptor ID |
D000067758
|
| MeSH Number(s) |
D12.776.543.750.695.021.600 D12.776.543.750.750.360.100.600
|
| Concept/Terms |
Glucagon-Like Peptide-2 Receptor- Glucagon-Like Peptide-2 Receptor
- Peptide-2 Receptor, Glucagon-Like
- Receptor, Glucagon-Like Peptide-2
- GLP-2 Receptor
- GLP 2 Receptor
- Receptor, GLP-2
- GLP2R Protein
- Protein, GLP2R
- Glucagon-Like Peptide 2 Receptor
- Glucagon Like Peptide 2 Receptor
- GLP-2R Receptor
- GLP 2R Receptor
- Receptor, GLP-2R
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide-2 Receptor".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide-2 Receptor".
This graph shows the total number of publications written about "Glucagon-Like Peptide-2 Receptor" by people in this website by year, and whether "Glucagon-Like Peptide-2 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 | | 2017 | 1 | 2 | 3 | | 2018 | 0 | 3 | 3 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2024 | 0 | 2 | 2 | | 2025 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide-2 Receptor" by people in Profiles.
-
Shah VN, Dex T, Meneghini L, Rodrigues A, Polonsky WH. Treatment satisfaction and time in range after 16?weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 May; 27(5):2523-2530.
-
FrÃas JP, Ratzki-Leewing A, Dex T, Meneghini L, Rodrigues A, Shah VN. Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 Apr; 27(4):2173-2182.
-
Zeitler P, Galindo RJ, Davies MJ, Bergman BK, Thieu VT, Nicolay C, Allen S, Heine RJ, Lee CJ. Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Diabetes Care. 2024 06 01; 47(6):1056-1064.
-
Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 06; 26(6):367-374.
-
Panaro BL, Yusta B, Matthews D, Koehler JA, Song Y, Sandoval DA, Drucker DJ. Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion. Mol Metab. 2020 07; 37:100990.
-
Davidson JA, Desouza C, Fonseca V, Frias JP, Van Gaal L, Giorgino F, Chao J, Dex TA, Roberts M, Saremi A, Leiter LA. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. Diabet Med. 2020 02; 37(2):256-266.
-
Trujillo JM, Roberts M, Dex T, Chao J, White J, LaSalle J. Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes Obes Metab. 2018 11; 20(11):2690-2694.
-
Johnson EL, Frias JP, Trujillo JM. Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin. Postgrad Med. 2018 May; 130(4):365-374.
-
Tonneijck L, Muskiet MHA, Smits MM, Bjornstad P, Kramer MHH, Diamant M, Hoorn EJ, Joles JA, van Raalte DH. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. Diabetes Obes Metab. 2018 05; 20(5):1235-1245.
-
Trujillo JM, Goldman J. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. Pharmacotherapy. 2017 Aug; 37(8):927-943.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|